Guidant contractor subpoenaed
This article was originally published in The Gray Sheet
Executive Summary
Contract manufacturer Accellent announces it has received a subpoena from the U.S. Attorney's Office in Minneapolis in a Nov. 21 8-K filing with the Securities & Exchange Commission. The subpoena, issued Oct. 28, requests documents relating to polyimide products the firm produces, which Guidant uses as an insulator for implantable cardioverter defibrillators and in other products. The New York Times has previously reported that the deterioration of this material under certain conditions might have played a role in some of the ICD malfunctions reported by the company during the past six months. The Accellent subpoena is connected with an investigation by the Attorney's Office relating to several of the firm's ICD products (1"The Gray Sheet" Oct. 31, 2005, p. 3)...
You may also be interested in...
Cardiac Rhythm Management Firms Targeted By DoJ Fraud Investigation
Subpoenas served to Guidant, Medtronic and St. Jude Medical by the U.S. Department of Justice appear to be investigating potential improper inducements to increase sales of pacemakers and ICDs
FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.
Keeping Track: Return & Renewal At US FDA
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.